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Abstract
Tumor growth and spread are a complicated matter and are the result of many
interconnected factors. The analysis of patterns emerging from highly numerous
populations might help shed some light on such an intricate mechanism. In this
respect, our studies are mostly based on the SEER database, a nation representative
dataset collecting data regarding the US population, over a very long time span. This
approach is revealed to be particularly useful for rare tumors, as prospective studies
are not feasible. Here, we present the results and the clinical implications of our
inquires: we show the impact on overall survival of several morphological and demo-
graphic characteristics of various malignancies including anorectal melanoma and
neuroendocrine tumors of the appendix. The impact of surgical treatment is
discussed as well. Finally, we endorse the need to find more reliable markers of tumor
biology, such as genetic patterns, to tailor an effective multidisciplinary treatment.
Keywords: neuroendocrine tumors of the appendix, anorectal melanoma,
multidisciplinary treatment, lymph node spread, carcinoid tumors
1. Introduction
Tumor progression is the result of several complex and interrelated mechanisms.
Apart from stage of the disease, biologic features of the neoplastic cell play a
relevant role. Size, location, grading, cell differentiation, genotype mutation, and
expression of oncogene are well-known features of the primary tumor all responsi-
ble for tumor progression and disease aggressiveness. Progression of the disease
may occur either as a result of local growth and invasion or by means of distant
spread of the disease in targeted organs via lymphatic or venous outflow. The two
phenomena are a consequence of specific biologic features of the neoplastic cell and
thus may occur independently from each other.
Rare tumors are particularly difficult to investigate, since prospective analyses
are not easy to plan due to the small number of patients observed and treated.
Therefore, reliable prognostic information are lacking or are controversial. Neuro-
endocrine tumor in general and those located in the appendix in particular are
subjected to several controversies. Size and histology of appendiceal carcinoids, for
instance, seem to influence heavily lymphatic spread and thus prognosis. Surgical
strategy is debated in consequence of such features with the aim of obtaining
adequate lymph node harvesting to establish a correct stadiation and prognosis.
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As far as recto-anal melanoma is concerned, prognosis is very poor due to
frequent diagnostic delay and rarity of the disease leading to misdiagnosis and
advanced stage at presentation. However, in spite of poor prognosis, extensive
surgery is still advocated although the experiences reported in the literature are
very limited and sparse, undoubtedly weak to support such aggressive approach.
Thus, since high-quality data regarding rare diseases such as appendiceal carci-
noids or anorectal melanoma neither are presently available nor can be obtained
prospectively in a short time, a reasonable approach to partially overcome such
limitations is to analyze a pool of data in large tumor registry, collecting retrospec-
tive cases. In order to maximize the statistical power of the study, potential con-
founders by means of multivariate analysis must be taken into account.
Mathematical models can be adopted to achieve such a goal; in particular Cox
regression models or matching populations by the propensity score can be success-
fully adopted. Populations can be described by using descriptive statistical methods
for categorical and continuous variables.
We planned a study on appendiceal carcinoids and anorectal melanoma
accessing the Surveillance, Epidemiology, and End Results (SEER) database, a
dataset collecting a large amount of data pertaining cancer in the US population
over a time span of decades.
We were able to demonstrate the impact on overall survival of different mor-
phological and demographic characteristics of anorectal melanoma and neuroendo-
crine tumors of the appendix [1–4], discussing their impact on surgical treatment
and prognosis.
We accessed the SEER database to retrieve the data to analyze. Then, we
selected the variables that we wanted to introduce in our models to assess their
impact on survival. In any statistical test performed, P < 0.05 was considered
significant. The covariates we focused on were demographic and morphologic. In
most occasions, we retrieved data on age of the patients, gender, stage of disease,
ethnicity, tumor size, and lymph node invasion.
2. Melanoma of the anorectum
Melanoma of the anorectum has a dismal prognosis since frequent early metas-
tases make any treatment ineffective, despite a multimodal approach [5]. The
rectum and anal canal represent the third most common primary site of origin [6].
The resemblance to benign common conditions such as hemorrhoids often delays
the diagnosis, strongly impairing the possibility of treatment with intention to cure
(Figure 1) (Table 1).
Site of origin is a determining prognostic factor for cutaneous melanoma [7].
With regard to mucosal melanomas, vulvar tumors proved a better outcome than
those originating from the vagina [8]. Our interest was based on the fact that
although most of the tumors arise in the anal canal, a not negligible percentage of
the neoplasia is located more proximally in the rectum [9]. It seems reasonable that
distal tumors could have a better prognosis, because they are clinically apparent
sooner than more proximal masses. The latter, in fact, tend to become apparent only
when symptoms of occlusion of the large intestine ensue. Moreover, anorectal
melanomas arising in the anus/anal canal or rectum drain in different lymph node
chains. To verify such hypothesis, we investigated the impact of site of origin on
overall survival. Bello et al. [10] showed different patterns of local recurrence:
anorectal melanoma recurred more often systemically, whereas tumors of the anal
canal recurred first at inguinal lymph nodes. However, the overall survival did not
vary between the groups. Our results confirmed that the site of origin along the
rectum and anal canal does not influence survival (P = 0.164).
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Stage of disease did not prove to have an impact on survival (P = 0.880 for
regional stage and P = 0.347 for distant stage). However, our results should be
considered with caution, given that we had to use the SEER historical stage classifi-
cation to obtain data consistent through time. In fact, the TNM has been changing
over time, and we decided to avoid its use, in order to not reduce the overall
number of cases available for final analysis. In other studies, stage showed a signif-
icant impact on survival [11, 12].
Figure 1.
Survival curve for patients affected by anorectal melanoma.
Category P value Hazard ratio Confidence interval
Site of origin (rectum) 0.275 1.233 0.845–1.798
Gender (male) 0.707 0.932 0.646–1.344
Size 0.519 1.000 0.998–1.001
Race (other) 0.019 2.291 1.148–4.575
Race (White) 0.824 0.945 0.571–1.562
LN rate 0.027 1.873 1.076–3.261
Age 0.150 1.010 0.997–1.023
Surgical intervention (APR/AR) 0.194 0.783 0.541–1.133
Stage (regional) 0.880 1.035 0.659–1.628
Stage (distant) 0.347 1.241 0.792–1.945
Radiation (performed) 0.150 1.461 0.870–2.452
Lymphadenectomy (performed) 0.904 0.977 0.663–1.438
Table 1.
Cox regression model for anorectal melanoma.
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In addition, we inquired the prognostic value of locoregional metastatic lymph
nodes and the impact of lymphadenectomy on overall survival. To better understand
the role of lymph nodemetastasis on prognosis, we introduced the concept of lymph
node ratio, defined as the ratio betweenmetastatic lymph nodes and total lymph nodes
harvested. This was necessary to avoid bias related to the extent of lymphadenectomy.
In our series, performing lymphadenectomydid not improve survival (P = 0.904). This
could be due to early tumor spread to distant sites, thus overcoming the potential
benefits of local control. Sentinel lymph node biopsy has not proven to be useful in
anorectal melanoma due to the low rate of positive findings, despite the presence of
more distant metastases [13]. Therefore, lymph node spread of anorectal melanoma is
far less predictable than, for example, the carcinoma of the breast.
Size of the tumor did not affect survival (P = 0.519), although it was previously
associated with an increased risk of mesorectal and mesenteric lymph node metas-
tases in anorectal melanoma [14]. Gender (P = 0.707) and age of the patient at time
of diagnosis (P = 0.150) did not affect survival as well. Interestingly, ethnicity was
found to be an independent predictor of survival (P = 0.019). Specifically, Ameri-
can Indian/Alaskan Native and Asian/Pacific Islander (other) ethnicity showed a
worse outcome.
Radical surgery is the best option for cure and should be the goal of treatment
[15, 16]. Optimal surgical strategies need to balance the need for radical excision
including lymphadenectomy against increasing operative morbidity. Consistently
with the recent literature, the type of surgical intervention was not a significant
prognostic factor (P = 0.183). The fundamental dilemma regarding the treatment of
anorectal melanoma is the choice between abdominoperineal/anterior resection and
local wide excision. Previous studies suggested that aggressive treatment could
provide better overall results by achieving local oncological control of the disease.
More recently, another trend of treatment has been emerging. According to
Matsuda et al. [17], no significant differences between the two options of treatment
in terms of overall survival were apparent. Abdominoperineal resection has failed to
show any advantage in terms of survival, adding a higher morbidity and poorer
quality of life. Thus, local excision has now become the standard of treatment. In
case of tumor recurrence, abdominoperineal or anterior resection can be performed
as a salvage procedure [18, 19].
Radiation therapy did not influence prognosis (P = 0.864), although it has been
demonstrated to provide better local control, especially in patients undergoing local
excision [20]. The reason stands on the fact that multifocality of the disease and
radial microscopic spread make effective radical excision difficult. Targeted or
systemic immunotherapy as well as regional chemotherapy has been described to
improve overall survival in patients with pelvic recurrences [21–23]. Molecular
analysis of recurrence melanoma is an important factor in determining which type
of therapy should be adopted [24]. However, better local control is ineffective when
distant spread has occurred early in the natural history of the disease.
Interestingly, race resulted to be associated with prognosis. In particular, Span-
ish people showed a more than double hazard ratio of death as compared to African
Americans. Although this result might be intriguing, we do not have sufficient data
to discuss it, given the lack of genetic analyses regarding our series. Probably, both
genetic and environmental factors may play a role.
3. Appendiceal neuroendocrine tumors
Current surgical strategy for primary neuroendocrine tumors of the appendix is
mostly based on tumor size. Right hemicolectomy is warranted for neuroendocrine
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tumors larger than 2 cm in diameter, whereas appendectomy alone is performed for
tumors smaller than 1 cm. Patients affected by neuroendocrine tumors with a
diameter of 1–2 cm are candidates for hemicolectomy in case of invasion of the
cecum or mesoappendix or infiltration of the lymph-vascular system [25]. This
treatment algorithm was introduced on the basis of retrospective outcome data
provided by Moertel and his colleagues. The disease is usually quite indolent, and
overall survival is good [26] (Table 2).
At present, there is no proof of survival benefits of right hemicolectomy com-
pared to appendectomy alone. In one of our studies, we wanted to verify whether
2 cm is a good cutoff value for identifying the best candidates for right
hemicolectomy. The indication for such a procedure in patients with neuroendo-
crine tumors larger than 2 cm in diameter stands on the augmented risk of visceral
lymph node involvement. In fact, tumor size is a predictor of nodal spread [27].
Assuming that there may be a progression from positive lymph nodes to distant
metastases, hemicolectomy is recommended to achieve oncologic radicality. It has
been argued that a more extended procedure may have a staging value, but not an
actual impact on survival [28].
Our data showed that the type of surgical procedure did not reach statistical
significance (P = 0.513), proving that an extended procedure does not confer a
survival advantage. Such findings and the indolent course of the disease suggest that
formal right hemicolectomy should be performed in young healthy patients,
whereas those burdened with comorbidities can be treated with appendectomy
without affecting oncologic outcomes. In other words, tumor size greater than 2 cm
should not be considered an absolute indication for right hemicolectomy.
In another study, we focused on the natural history of metastatic lymph nodes
and their clinical impact for primary pure and mixed neuroendocrine tumors of the
appendix (Figure 2). The rationale for the surgical treatment is based on the risk of
lymph node spread. However, the role of such an event on the natural history of the
disease is not clear. First, the survival curve of our populations showed that pure
carcinoids have a better prognosis than those with mixed variants (P < 0.001).
After controlling for age, sex, tumor size, surgical intervention, and lymph nodes
rate, a Cox proportional hazards model showed that histology was an independent
predictor of overall survival (P = 0.004). This suggested that pure and mixed
carcinoids differ with respect to their biological aggressiveness. For that reason, we
analyzed patients having either pure or mixed carcinoids as two distinct series.
Interaction* (P value) Group P value Hazard ratio Confidence interval
Gender (female) 0.066 Pure 0.154 0.538 0.229–1.263
Mixed 0.347 1.201 0.820–1.758
Tumor size (≤2 cm) 0.017 Pure 0.896 0.937 0.355–2.474
Mixed <0.001 0.442 0.286–0.683
Surgical intervention
(less than RHC)
0.017 Pure 0.029 0.241 0.067–0.867
Mixed 0.019 1.675 1.088–2.578
Age <0.001 Pure <0.001 1.083 1.051–1.116
Mixed <0.001 1.041 1.026–1.056
LN rate 0.012 Pure 0.039 5.295 1.089–25.754
Mixed <0.001 17.471 10.4733.382
Table 2.
Cox regression models for neuroendocrine tumors.
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Age and surgical intervention (less than right hemicolectomy compared to
hemicolectomy or more extended procedure) were found to be independent prog-
nostic factors for both pure (P < 0.001 and P < 0.001) and mixed carcinoids
(P = 0.029 and P = 0.019). In the latter group, tumor size (P < 0.001) was another
independent predictor of survival. It is well established that the biological behavior
of mixed neuroendocrine tumors can somewhat resemble that of adenocarcinoma,
therefore showing a more aggressive behavior. Lymph node rate was found to have
a strong independent negative impact on survival for both pure (P = 0.039) and
mixed neuroendocrine tumors (P < 0.001). Metastatic spread to lymph nodes is
thus of major importance to both groups. The presence of metastatic nodes largely
affects overall survival and represents a reliable clinical hallmark of the aggressive-
ness of these tumors.
Right hemicolectomy or a more extended procedure exerted a significant pro-
tective effect with pure neuroendocrine tumors and a negative effect with mixed
neuroendocrine tumors. This controversial result could be related to the higher
frequency of distant metastases in the mixed group, although we were unable to test
that idea because of the limitations of the SEER database.
Our studies however suffer from several limitations due to their retrospective
nature and to well-known shortcomings of the SEER database. Some data were
missing, thus limiting the numerosity of the populations. Moreover, the SEER
database provides only a certain type of variable and no entries regarding aspects
Figure 2.
Survival curve for patients affected by neuroendocrine tumors, according to lymph node status.
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related to molecular biology. However, these are the best data available, when it is
not feasible to design randomized prospective studies.
4. Conclusion
Tumor growth and spread are complex processes. Rare diseases are the most
difficult to analyze, due to controversial issues and lack of data. Moreover, mor-
phologic data retrieved from large databases do not always provide accurate results
regarding the biologic aggressiveness and survival. Therefore, molecular biology
markers and genetic profiling should be the basis of future investigations.
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